Individuals with 22q11.2 deletion syndrome (22q11.2DS) are at elevated risk of developing treatable psychiatric and neurological disorders, including anxiety disorders, schizophrenia, seizures, and movement disorders, often beginning in adolescence or early to mid-adulthood. Here, we provide an overview of neuropsychiatric features associated with 22q11.2DS in adulthood. Results of a new case series of 13 individuals with 22q11.2DS and catatonic features together with 5 previously reported cases support a potential association of this serious psychomotor phenotype with the 22q11.2 deletion. As in the general population, catatonic features in 22q11.2DS occurred in individuals with schizophrenia, other psychotic and non-psychotic psychiatric disorders, and neurological disorders like Parkinson's disease. We place the results in the context of an updated review of catatonia in other genetic conditions. The complex neuropsychiatric expression and risk profile of 22q11.2DS highlights the need to consider co-morbid factors and provide care tailored to the individual patient. The results reinforce the need for periodic monitoring for the emergence of psychiatric and neurological manifestations including catatonic features. Pending further research, enhanced recognition and informed anticipatory care promise to facilitate the early diagnosis that allows for timely implementation and optimization of effective treatments.
| I N TR ODU C TI ON
The phenotypic expression of 22q11.2 deletion syndrome (22q11.2DS) is variable between individuals and across the lifespan Fung et al., 2015) . Survival to adulthood is the norm, related in part to advances in pediatric care, for example, of associated features such as congenital cardiac and other anomalies McDonald-McGinn et al., 2015) . Thus, there is an urgent need to better understand and manage the persisting and later onset features of the 22q11.2DS phenotype. Major neuropsychiatric manifestations that may affect the adult 22q11.2DS population include intellectual disability, anxiety disorders, schizophrenia, seizures/epilepsy, and Parkinson's disease (Bassett, Costain, & Marshall, 2017; Butcher et al., 2013; Fung et al., 2015; Wither et al., 2017) . Psychiatric disorders comprise the most common group of later onset manifestations associated with 22q11.2DS (Bassett et al., 2005; Fung et al., 2010; Philip & Bassett, 2011) . The one in four risk of developing schizophrenia in 22q11.2DS is of particular concern to patients and their families given its potential seriousness, associated stigma, and impact on functioning (Butcher et al., 2012; Hercher & Bruenner, 2008; Karas, Costain, Chow, & Bassett, 2014 ). Parkinson's disease and other neuromotor features have also emerged as important aspects of the adult expression of 22q11.2DS Butcher et al., 2013 Butcher et al., , 2017 Mok et al., 2016 ).
Here, we provide an overview of the psychiatric, neurological, and co-morbid features associated with 22q11.2DS in adulthood. To illustrate the complex neuropsychiatric expression and multiple confounding factors often associated with the syndrome, we present a new case series of 13 patients with 22q11.2DS who demonstrated features of catatonia, a complex psychomotor phenotype that may be another manifestation of 22q11.2DS. In this context, we also review five previously reported cases and the literature on other genetic conditions with catatonia.
| N E U ROP S Y CHI A TR I C M A N I FE S TA TI ON S OF 2q 1 1.DS

| Schizophrenia and other psychotic disorders
Individuals with 22q11.2DS are at about 25-fold increased risk of developing a psychotic illness, such as schizophrenia or schizoaffective disorder, over population expectations McDonaldMcGinn et al., 2015) . The schizophrenia associated with 22q11.2DS accounts for 0.5-1% of schizophrenia in the general population and is indistinguishable from other forms of schizophrenia with respect to prodrome, age at onset, the core signs and symptoms, and cognitive profile, with the exception of overall lower average IQ and the absence of sex differences (Bassett et al., 2003; Chow, Watson, Young, & Bassett, 2006; Fung et al., 2015; Karayiorgou, Simon, & Gogos, 2010; van Amelsvoort et al., 2004) . Symptoms include delusions, hallucinations, disorganized thinking, disorganized emotional expression and/or behavior, as well as blunted affect, reduced speech, social withdrawal, and motor disturbances (Tandon et al., 2013; Walther & Strik, 2012) .
While mood disorders with psychotic features are reported, there is no evidence that prevalence is greater than general population expectations (Fung et al., 2015) .
| Non-psychotic disorders
Other psychiatric disorders that do not involve psychosis also occur in adults with 22q11.2DS at elevated rates . Most common are anxiety disorders that may emerge during adulthood or persist from childhood and are reported in approximately 30% of adolescents and adults with 22q11.2DS, including generalized anxiety disorder, social phobia, and/or panic disorder (Fung et al., 2010; Schneider et al., 2014) . Rates of depression do not appear to be elevated (Fung et al., 2010) . Attention deficit hyperactivity disorder persists to adulthood in as many as 15% of adults with 22q11.2DS, most commonly manifesting as the inattentive subtype (Schneider et al., 2014) . Notably, the presence of childhood autism spectrum disorders (ASDs) in 22q11.2DS appears to be unrelated to the later appearance of schizophrenia (Fiksinski et al., 2017; Vorstman, Breetvelt, Thode, Chow, & Bassett, 2013) . Even though the symptoms of ASD usually persist throughout life, to date there are no reports of ASD in cohorts of adult patients with 22q11.2DS, possibly because systematic diagnostic screening for ASD is not part of most standard assessment of adults.
| Seizure disorders
All types of seizures have been associated with 22q11.2DS (Table 1) and may emerge at any age (Fung et al., 2015; Kao et al., 2004; Wither et al., 2017) . Seizures in patients with 22q11.2DS may be unprovoked, or related to factors such as hypocalcemia, psychiatric medication use, neurodevelopmental cortical malformations, fever, hypoxia, ischemia, or surgery. The associated seizures can be of generalized or focal onset.
A recent study found that 4% of adults with 22q11.2DS met diagnostic criteria for epilepsy (Wither et al., 2017) , higher than general population estimates (0.5-1%). Seizures may involve abnormal and/or repetitive movements such as twitching and abnormal postures, and importantly, may be difficult to distinguish from other causes of such neurological symptoms (Benbadis, 2009 ).
| Parkinson's disease and neurodegenerative features
with classical Parkinson's disease, though with early-onset (i.e., <50 years) and variable presence of typical Lewy bodies on postmortem (Booij, van Amelsvoort, & Boot, 2010; Butcher et al., 2013; Mok et al., 2016; Zaleski et al., 2009) . Diagnostic delays were reported in individuals with comorbid schizophrenia, likely related to difficulties differentiating Parkinson's disease symptoms from antipsychotic-related parkinsonism (Butcher et al., 2013) . Profound cognitive deterioration of unknown etiology has also been reported in some 22q11.2DS patients with intellectual disability and psychosis (Evers et al., 2014b) .
| Other movement disorders and motor abnormalities
Psychiatric disorders and/or their associated treatments may cause or contribute to the manifestation of motor symptoms in 22q11.2DS (Table 1) The antipsychotic medications that are the mainstay of treatment for schizophrenia have the potential to induce, exacerbate, or, interestingly, diminish pre-existing movement disorders in some cases (Peluso, Lewis, Barnes, & Jones, 2012) . Other psychotropic medications commonly used in 22q11.2DS such as antidepressants and anticonvulsants can also cause adverse motor effects (Damsa et al., 2004; Kennedy & Lhatoo, 2008) . Case reports suggest an increased vulnerability to antipsychotic-related movement disorders in 22q11.2DS that may include drug-induced parkinsonism, non-epileptic myoclonus, and dystonia Butcher et al., 2017; Kontoangelos, Maillis, Maltezou, Tsiori, & Papageorgiou, 2015) .
Parkinsonian motor symptoms may also be manifestations of 22q11.2DS itself. For example, a recent study of adults with 22q11.2DS revealed elevated rates of bradykinesia, rigidity, postural instability, and tremor relative to healthy age-matched controls . Bradykinesia was the most common feature, affecting those with and without psychotic illness. Longitudinal studies will be needed to evaluate to what extent these symptoms may represent prodromal signs of Parkinson's disease. Boot et al. (2015) . Monitoring and treatment recommendations for 22q11.2DS are described in detail elsewhere  2.6 | Functional neurological disorders
Psychogenic or functional neurological disorders may, with caution, be considered in the differential diagnoses for patients with 22q11.2DS (Table 1) . Anecdotally, these cases have infrequently presented in clinical practice (e.g., psychogenic non-epileptic seizures or parkinsonism).
A psychogenic/functional neurological disorder should only be considered in consultation with a clinician having significant expertise in the relevant fields (e.g., epilepsy, movement disorders) and preferably also with expertise in 22q11.2DS, given the complexities of diagnosis and management (Espay & Lang, 2015; Milan-Tomas, Persyko, Del Campo, Shapiro, & Farcnik, 2018) .
| G EN ER A L PR I N CI P LE S OF M A N AG EM E NT F OR N E U ROP SY CHI A TR I C D I SOR DE RS IN 2 2q 1 1.2 DS
The management of neuropsychiatric disorders in adults with 22q11.2DS follows the same biopsychosocial principles as those applied in the general population; this has been described in detail elsewhere (Fung et al., 2015) .
| Assessment
Assessment and monitoring for neuropsychiatric expression in 
| Pharmacological management
For psychiatric illnesses associated with 22q11.2DS, management according to general population clinical practice guidelines is indicated Fung et al., 2015) . There are however some additional considerations, particularly for antipsychotic medications. These include the potential for a lowered seizure threshold Wither et al., 2017) , vulnerability to movement disorders Butcher et al., 2013 Butcher et al., , 2017 , and a propensity to obesity (Voll et al., 2017) . Notably, none of these considerations precludes the use of any particular group of psychotropic medications in 22q11.2DS.
For example, a "start low and go slow" approach to dosing and concomitant anticonvulsant use may help ameliorate the increased seizure
risk associated with what is arguably the most effective antipsychotic,
clozapine, that has demonstrated efficacy in 22q11.2DS . Clozapine, often under-utilized in clinical practice (Farooq & Taylor, 2011) , is of especially low risk to cause or aggravate motor disturbances (Caroff, Hurford, Lybrand, & Campbell, 2011) and has been used to manage tremor and psychosis in Parkinson's disease (Thomas & Friedman, 2010) .
Similarly, standard pharmacological treatments for neurological disorders are recommended, for example, dopaminergic therapy for Parkinson's disease (Table 1) . Published case reports suggest typical response to standard anticonvulsant medications for managing seizure disorders (Gonzalez & Bautista, 2009; Kao et al., 2004) . Some anticonvulsants may also help ameliorate psychiatric symptoms (Kaufman, 2011) . However, it is important to keep in mind that certain antiepileptic drugs such as valproate are associated with parkinsonism (Brugger, Bhatia, & Besag, 2016) . Notably, oculogyric crisis, a dystonic complication of antipsychotics, may be misinterpreted as a seizure, leading to unnecessary use or increase in doses of anticonvulsants.
| Non-pharmacological interventions
To date, no study has directly investigated non-pharmacological therapies for a psychiatric disorder in 22q11.2DS (Buijs, Bassett, & Boot, 2018 ). This includes evidence-based effective treatments such as electroconvulsive therapy (ECT) and cognitive-behavioral therapy. However, there are a few preliminary studies of 22q11.2DS involving computer-based and group interventions aimed at improving the neuropsychological deficits that may be associated with psychiatric disorders (Buijs, Bassett, & Boot, 2018) . Areas of relative strength in adult functioning in 22q11.2DS that could help inform expectations and planning are outlined elsewhere (Butcher et al., 2012) .
| Concomitant medical features
Appropriate management of other concomitant medical comorbidities are recommended for all patients with 22q11.2DS (Table 1) (Fung et al., 2015) . For example, hypocalcemia can arise at any age and affects the majority (>60%) of adult patients (Cheung et al., 2014b; McDonald-McGinn et al., 2015) . While often asymptomatic, hypocalcemia can be associated with neuropsychiatric symptoms, including irritability, fatigue, tremor, muscle cramps, stiffness, and seizures Kao et al., 2004; Weinzimer, 2001; Yu, 2014) . Notably, some anticonvulsants, such as carbamazepine and phenytoin, may diminish vitamin D levels (Teagarden, Meador, & Loring, 2014) , potentially increasing the risk of hypocalcemia (Cheung et al., 2014b) and its associated complications. Thyroid disease affects up to one in four patients with 22q11.2DS (Bassett et al., 2005; Cheung et al., 2014a) , and similarly may have symptoms or side effects of treatment that can be confused with psychiatric symptoms or overlap with motor features.
Disruptions in sleep pattern and the increased risk for obstructive sleep apnea, an understudied feature in 22q11.2DS (Kennedy et al., 2014) , and congenital musculoskeletal abnormalities, also warrant consideration in the context of neuropsychiatric symptoms including motor functioning (Table 1) .
| C AT AT ONIA A S A CO MP L EX N E U ROP S YC HI A TR I C M A N IF E S TA TI ON I N 2 2q 1 1.2 DS
In the context of prominent neuropsychiatric expression in 22q11.2DS
and a recent study reporting on copy number variations in adults with catatonia (Breckpot et al., 2016) , we examined catatonic features as part of neuropsychiatric expression (Table 2) . Catatonia is a complex psychomotor phenotype, defined in the DSM-5 (Tandon et al., 2013) as the presence of three or more of the following: (a) catalepsy (i.e., another's movements). The DSM-5 allows diagnosis of catatonia as a specifier to multiple neuropsychiatric disorders (including schizophrenia and other psychotic disorders, major mood disorders) or general medical conditions, or as "catatonia not otherwise specified" (Solmi et al., 2017; Tandon et al., 2013) .
Catatonia is important to recognize both because of its severity and the immediate treatment implications. Catatonia can be lifethreatening in the form of "malignant" catatonia associated with autonomic dysfunction, hyperthermia, and altered consciousness (Rasmussen, Mazurek, & Rosebush, 2016 ) that may be indistinguishable from neuroleptic malignant or toxic serotonin syndromes (Fink & Taylor, 2009 ). Specific management with proven efficacy includes lorazepam, often provided intravenously (4-20 mg/day), or ECT (Fink & Taylor, 2009; Luchini et al., 2015; Peralta et al., 2010) . These treatments may be less effective however when catatonia is associated with schizophrenia compared with catatonia associated with mood or other disorders (Ungvari, Caroff, & Gerevich, 2010) .
| Case series of patients with 22q11.2DS presenting with catatonic features
In addition to summarizing the five previous reports of 22q11.2DS
patients with catatonic features (Faedda, Wachtel, Higgins, & Shprintzen, 2015; Graf et al., 2001; Sachdev, 2002; Sieberer et NB. All but 2 of the 13 cases in the new case series had a history of at least one endocrine disorder (hypocalcemia, n 5 9; hypoparathyroidism, n 5 6; hypothyroidism, n 5 4; type 2 diabetes, n 5 4; hypomagnesemia, n 5 3; data not shown), consistent with the multisystem nature of 22q11.2DS (Fung et al., 2015 (Dean, Data-Franco, Giorlando, & Berk, 2012) ; Case in Graf et al. (2001) , metyrosine (alpha-methyl-para-tyrosine), a competitive inhibitor of tyrosine hydroxylase, the rate-limiting enzyme of catecholamine synthesis (Bloemen, de Koning, Boot, Booij, & van Amelsvoort, 2008) .
d
Additional details on Case 12 with PD previously reported elsewhere (Butcher et al., 2013 .
Philadelphia 22q and You Center). We included all individuals with molecularly confirmed 22q11.2 deletions where the term "catatonia" or symptoms attributed to catatonia were described. We extracted information on the features of catatonia, response to treatment, and relevant demographic and clinical characteristics including lifetime neuropsychiatric phenotypes. There were no standardized scales for catatonia identified in the charts reviewed. We used the data available and applied DSM-5 criteria to determine whether a retrospective diagnosis of catatonia was warranted. We present results for the 13 subjects (9 female) in our new case series and the 5 previously published cases (4 female) together in Table 2 , given the small numbers involved.
Also, to place the results for 22q11.2DS in the broader context of the genetics of catatonia, we used Online Mendelian Inheritance in Man,
supplemented by a recent study of catatonia and copy number variation (Breckpot et al., 2016) and reference list searching to identify and synthesize reports of other genetic variants identified in patients with catatonia (Table 3) . Table 2 summarizes the results recorded for the total 18 cases (n 5 13, 72% female) identified. Catatonic symptoms had a median onset of 22 (range 12-60) years. Seven patients, including four from the new case series, met criteria for DSM-5 catatonia (i.e., three or more catatonia features); seven others (six in the new case series) had two of these features documented. There were diverse intellectual levels and lifetime histories of neurological and psychiatric disorders for these patients. While all but one patient had a lifetime history of schizophrenia or other psychotic disorder, the later age at onset of catatonic features and/or response to treatment suggested a possible relationship to Parkinson's disease or other neurological findings in some patients (e.g., case 12, Table 2 ).
Notably, relatively few of the patients were reported to have received specific treatment for catatonic features (Table 2 ). Response to ECT was reported to be dramatic for one patient with just one catatonic feature documented (case 10), but limited for a patient who responded to standard levodopa/carbidopa treatment of Parkinson's disease (case 12). Although there were reports of positive response of catatonic features to second generation antipsychotic medications for 11 of the 14 with catatonic features having onset age 25 years or younger, in the context of a major psychotic illness, 7 of these patients were also receiving a benzodiazepine at last assessment. Other signs that diagnosis and management appeared challenging included unsuccessful trials of intravenous immunoglobulin therapy for suspected autoimmune encephalopathy in 2 patients and poor outcomes for 4 others, including one where neuroleptic malignant syndrome was suspected (Table 2 ).
| Genetics and proposed mechanisms of catatonia
This report adds to the growing literature on genetic anomalies that may be associated with catatonia, including other recurrent copy number variations and chromosomal abnormalities (Table 3) . Although perhaps related to the prevalence of 22q11.2 deletions, no other genetic anomaly has more reported cases of individuals with catatonia and/or catatonic features (Table 3) . As may be expected for a complex neuropsychiatric condition such as catatonia, there may be numerous genetic and other causative/risk factors that lead to the same clinical endpoint. Identification of genetic risk variants may provide novel insights into its underlying pathophysiology, which remains poorly understood. There is evidence of dysfunction in multiple neurotransmitter systems reported for 22q11.2DS Butcher et al., 2017; da Silva Alves et al., 2011; Evers et al., 2014a) . Similarly, abnormalities in multiple central neurotransmitter systems, including dopamine, glutamate, and gammaaminobutryic acid (GABA), have been implicated in catatonia, in part by the response to benzodiazepines and ECT (Fornaro, 2011) . Interestingly, there is a report of catatonia in a patient with a PRODH mutation (Table   3 ) (Consoli et al., 2012) . The PRODH gene is located within the 22q11.2 deletion region and encodes a mitochondrial enzyme implicated in motor abnormalities and with functions including modulation of glutamatergic and GABA-ergic transmission (Guna, Butcher, & Bassett, 2015) .
| Advantages and limitations
This report provides an up-to-date synthesis of neuropsychiatric conditions associated with 22q11.2DS and management considerations in the context of the associated comorbidities. Also, it provides a comprehensive summary of catatonic features, and neuropsychiatric comorbidities and management, in 13 new and 5 previously reported patients.
Numbers are small however and only a minority met full DSM-5 criteria for catatonia. The retrospective case series was unavoidably limited to what was reported as "catatonia" and/or catatonic features in the available charts. Catatonia is often missed clinically (Ghaziuddin, Dhossche, & Marcotte, 2012) , thus it is likely that other cases remain unidentified.
On the other hand, particular caution may be required when diagnosing catatonia in patients with 22q11.2DS, given that the neuropsychiatric and medical comorbidities associated with 22q11.2DS have signs and symptoms, and treatments, that may overlap with and/or exacerbate symptoms of catatonia, as noted in general for catatonia (Bhati, Datto, & O'Reardon, 2007; Penland, Weder, & Tampi, 2006; Rasmussen et al., 2016) . The positive response to antipsychotic medications documented may suggest that the expression of catatonic features was related to the expression of psychotic illness in some of these 22q11.2DS cases.
In general, experts focus on benzodiazepine treatment and/or ECT to manage catatonia, recommending caution with primary antipsychotic treatment (Fink & Taylor, 2009; Paparrigopoulos, Tzavellas, Ferentinos, Mourikis, & Liappas, 2009 ). This study was not designed as a study of treatment however, and assessment of treatment response was mainly cross-sectional and limited by the data recorded.
| Implications and conclusions
Despite the limitations, with respect to catatonic features, the results collectively suggest that catatonia may be of clinical relevance to patients with 22q11.2DS, perhaps particularly in those with psychotic
illness. This appears consistent with findings for the 15q11q13 duplication (Table 3) , another rare recurrent copy number variation where there is high penetrance for schizophrenia and where expression may include catatonia (Isles et al., 2016 22q11.2DS, consistent with some reports for catatonia in schizophrenia (Ungvari et al., 2010) . The findings illustrate the need for prospective cohort studies to optimally assess the prevalence of catatonia and response to treatment in 22q11.2DS. Raised awareness of the possible association of catatonia in 22q11.2DS should aid recognition and may help improve both management and more accurate and timely diagnosis of catatonia and the associated conditions(s) that could contribute to the expression of catatonic features in this genetic population. These would include consideration of developmental stage/age and comorbidities (Figure 1) , and other motor disturbances including those sometimes reported in catatonia in the general population, for example, parkinsonism and other extrapyramidal symptoms, dyskinesia, and dystonia (Bush, Petrides, & Francis, 1997; Northoff et al., 1999; Shill & Stacy, 2000) . In all cases, standard assessments for catatonia, including careful history, physical examination, and catatonia rating scales (e.g., Bush-Francis Catatonia Rating Scale (Bush, Fink, Petrides, Dowling, & Francis, 1996) or others (Solmi et al., 2017) will be helpful to evaluate presence, severity, and course of symptoms. Genome-wide linkage to familial periodic catatonia (No mutations identified) Uncertain; VSP19 implicated 15q15 locus; deemed a schizophrenia susceptibility locus (SCZD10) for chromosome 15q15-related periodic catatonia (OMIM #605419) using linkage evidence from multiplex periodic catatonia families with a further potential locus at 22q13 in these families; VSP19 was proposed as a 15q15 locus candidate gene for schizophrenia and catatonia from de novo variants identified in a trio study Stober et al. (2002) and Xu et al. (2012) Note. ADHD 5 attention deficit hyperactivity disorder; ALS 5 amyotrophic lateral sclerosis; ASD 5 autism spectrum disorder; ECT 5 electroconvulsive therapy; ID 5 intellectual disability; kb 5 kilobase; Mb 5 megabase; NOS 5 not otherwise specified; OCD 5 obsessive compulsive disorder; OMIM 5 Online Mendelian Inheritance in Man; PDD 5 pervasive developmental disorder; PNOS 5 psychotic disorder not otherwise specified; UPD 5 uniparental disomy. a Confirmed D178N/129 M mutation of PRNP typical of fatal familial insomnia: Asp178-to-Asn mutation and homozygosity for methionine at position 129. 
